Who is sponsoring NCT05282329?

NCT05282329 is sponsored by Tianjin Anding Hospital.

What drugs are being tested in NCT05282329?

Interventions in NCT05282329: Transcranial alternating Current Stimulation (tACS)-active, Transcranial Alternating Current Stimulation (tACS)-sham.

What condition does NCT05282329 study?

NCT05282329 studies Schizophrenia.

Is NCT05282329 still recruiting?

NCT05282329 is currently completed. Last updated 7 October 2022.

Last reviewed 2022-10-07 · How we verify

NCT05282329

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of tACS for Treatment of Auditory Hallucinations in Refractory Schizophrenia

Completed NA Last updated 7 October 2022

What this trial tests

NA trial testing Transcranial alternating Current Stimulation (tACS)-active in Schizophrenia in 50 participants. Completed in 21 September 2022.

Timeline

1 September 2020

Primary endpoint
31 August 2022

21 September 2022

Quick facts

Lead sponsor	Tianjin Anding Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	1 September 2020
Primary completion	31 August 2022
Estimated completion	21 September 2022
Sites	1 location across China

Drugs / interventions tested

Transcranial alternating Current Stimulation (tACS)-active
Transcranial Alternating Current Stimulation (tACS)-sham

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Tianjin Anding Hospital

Who can join

Adults 18 to 70, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the feasibility and efficacy of transcranial alternating current stimulation (tACS) as an add-on treatment for auditory hallucinations in refractory schizophrenia. Meanwhile, we aim to evaluate the effect of tACS on cognitive function of schizophrenia patients. we hypothesize tACS would improve refractory auditory hallucination symptoms in schizophrenia by regulating the gamma frequency band of temporal lobe。

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Transcranial alternating current stimulation for neuropsychiatric disorders: a systematic review of treatment parameters and outcomes.
Gholamali Nezhad F, Martin J, Tassone VK, Swiderski A, et al · · 2024 · cited 7× · PMID 39211537 · DOI 10.3389/fpsyt.2024.1419243

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Tianjin Anding Hospital trials

Trials by the same sponsor.

NCT07393464 — PQQ for Cognitive and Negative Symptoms · NA · not yet recruiting
NCT07523490 — Investigation on Suicide Risk Factors of Patients With Mood Disorders · recruiting
NCT06812923 — TACS on High-inflammatory and Refractory Depression · NA · recruiting
NCT07162467 — Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia. · enrolling by invitation
NCT07359209 — Berberine Improving Cognitive Impairments in Schizophrenia · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05282329 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Anding Hospital
Last refreshed: 7 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05282329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing